Target
nal-IRI
1 abstract
Abstract
The clinical utility of plasma cell-free DNA (cfDNA) in NET-02: Randomised, phase II trial of liposomal irinotecan (nal-IRI)/5-fluorouracil (5-FU)/folinic acid or docetaxel as second-line (2L) therapy in patients (pts) with progressive poorly differentiated extra-pulmonary neuroendocrine carcinoma (PD-EP-NEC).Org: CRUK Manchester Institute, Leeds Institute of Clinical Trials Research, Newcastle Hospital NHS Foundation Trust, Leeds Teaching Hospitals NHS Trust, CRUK Cancer Biomarker Centre,